I. MODIFIED AGREEMENTS | |||
Biotech Co.* |
Pharma Co. |
Change from original |
Terms/Details (Date) |
Ariad |
Eli Lilly and Co. |
A District Court jury ruled Lilly's Evista and Xigris drugs infringed Ariad patents on treating disease by regulating NF-(kappa)B cell-signaling |
Ariad was awarded damages of $65.2M, representing a royalty rate of 2.3% and said it would get 2.3% of U.S. sales of the drugs through 2019; Lilly plans to challenge the verdict (5/4) |
Cytogen Corp. |
Berlex Inc. |
Cytogen bought out Berlex's royalty interest in Quadramet, an approved oncology product |
Berlex gets a payment of $6M and 623,441 Cytogen shares that were valued at about $2M; it also could get about $8.35M in sales-based milestone payments (5/8) |
Notes: | |||
# The information in the chart does not cover agreements between biotech companies or agricultural agreements. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. |